Photo: Cynthia S. Goldsmith, Russell Regner/CDC via AP, file
September 13, 2022 12:10 PM EDT
R&D
Pharma
FDA+

'Re­al­ly in­clude every­one in the tri­al': A Q&A with the pro­to­col chair of the PhI­II mon­key­pox an­tivi­ral study

Kyle LaHucik

Senior Reporter

On Sept. 8, the AIDS Clin­i­cal Tri­als Group and the Na­tion­al In­sti­tutes of Health be­gan a Phase III clin­i­cal tri­al of tecovir­i­mat, an an­tivi­ral ap­proved …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

FDA vac­cine chief Pe­ter Marks pledges to stay as long as he's wel­come

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times